Sandra Levy
ARTICLES BY THIS AUTHOR
- 1/3/2022
CDC shortens interval for Pfizer’s COVID-19 booster
People can now receive an mRNA booster shot five months after completing their Pfizer-BioNTech primary series. - 12/29/2021
Alembic intros generic Bactroban
Alembic's generic Bactroban provides a treatment for secondarily infected traumatic skin lesions due to susceptible isolates of Staphylococcus aureus and Streptococcus pyogenes. - 12/29/2021
FDA expected to expand COVID-19 booster eligibility for children ages 12 to 15
Approval of a COVID-19 booster for children ages 12 to 15 could come in the days to weeks ahead. - 12/29/2021
Eagle obtains 180 days marketing exclusivity for generic Vasostrict
Eagle Pharmaceuticals received 180 days of marketing exclusivity from the Food and Drug Administration for its recently approved generic version of Endo’s Vasostrict (vasopressin). - 12/27/2021
Novartis receives FDA OK for Leqvio
Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals. - 12/22/2021
IRI postpones 2022 Growth Summit
Amid the rise in COVID-19, IRI has postponed its Growth Summit until 2023. - 12/22/2021
Hy-Vee to host 5th “Best of Local Brands” summit in February
Midwestern vendors are invited to submit their products for potential Hy-Vee distribution, focus will be on diverse suppliers. - 12/22/2021
Hy-Vee debuts two websites with ship-to-home services
Hy-VeeDeals.com and ShopPetShip.com will bring Hy-Vee offerings to all 50 states. - 12/22/2021
FDA gives EU authorization for Molnupiravir
Molnupiravir received emergency use authorization for mild-to-moderate COVID-19 in adults. - 12/22/2021
ANI gets FDA OK for generic Mycobutin
Rifabutin capsules have a market value of approximately $16.6 million, according to IQVIA.
